Akari Therapeutics Q2 2026: Wider Loss, $7.7M Cash, Phase 1 Trial Set for Mid-2027
AKTX has more than doubled off its 52-week low of $3.015.
Summary
Akari Therapeutics reported a wider Q2 2026 net loss of $4.8 million and cash of $7.7 million, while highlighting progress toward a Phase 1 trial for AKTX-101 in mid-2027 and a new ADC collaboration.
Key Events · Earnings and Guidance · AKTX
-
Q2 Net Loss Widens
Net loss was $4.8 million for Q2 2026, compared with $1.9 million in Q2 2025, driven by higher R&D spending.
-
Cash Position
Cash totaled $7.7 million as of June 30, 2026, up from $5.2 million at year-end 2025 after raising $8.6 million in gross proceeds.
-
Phase 1 Trial Planned
Company remains on track to initiate a Phase 1 clinical trial for AKTX-101 in mid-2027.
-
Whitehawk Collaboration
Announced a research collaboration with Whitehawk Therapeutics to evaluate dual-payload ADCs combining PH1 and topoisomerase I platforms.
Analysis · AKTX · Life Sciences
A net loss of $4.8 million for Q2 2026—more than double the $1.9 million loss a year earlier—reflects a tripling of R&D spend to $2.1 million as Akari Therapeutics advances AKTX-101 toward clinical trials. Cash stands at $7.7 million after raising $8.6 million in gross proceeds during the quarter, providing runway but still tight for a company with a going-concern warning. The company also announced a strategic collaboration with Whitehawk Therapeutics and positive preclinical data at ASCO, but the near-term focus remains on capital needs and the mid-2027 Phase 1 timeline.
At the time of this filing, AKTX was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $3.02 to $49.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.